S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
NYSE:EW

Edwards Lifesciences - EW Stock Forecast, Price & News

$80.76
+1.21 (+1.52%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$79.37
$81.02
50-Day Range
$74.34
$84.51
52-Week Range
$67.13
$131.10
Volume
2.75 million shs
Average Volume
4.13 million shs
Market Capitalization
$48.95 billion
P/E Ratio
33.10
Dividend Yield
N/A
Price Target
$88.95

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Hold
2.39 Rating Score
Upside/​Downside
10.1% Upside
$88.95 Price Target
Short Interest
Healthy
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.74mentions of Edwards Lifesciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$7.90 M Sold Last Quarter
Proj. Earnings Growth
12.70%
From $2.52 to $2.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

87th out of 989 stocks

Surgical Appliances & Supplies Industry

7th out of 20 stocks


EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

StockNews.com Begins Coverage on Edwards Lifesciences (NYSE:EW)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Jefferies Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Credit Suisse Keeps Their Hold Rating on Edwards Lifesciences (EW)
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
1/31/2023
Today
3/25/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
17,300
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$88.95
High Stock Price Forecast
$134.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+10.1%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

Net Income
$1.52 billion
Pretax Margin
32.84%

Debt

Sales & Book Value

Annual Sales
$5.38 billion
Cash Flow
$2.70 per share
Book Value
$9.39 per share

Miscellaneous

Free Float
598,281,000
Market Cap
$48.95 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Michael A. MussallemMichael A. Mussallem
    Chairman & Chief Executive Officer
  • Bernard J. ZovighianBernard J. Zovighian
    President
  • Scott B. UllemScott B. Ullem
    Chief Financial Officer & Vice President
  • Todd J. Brinton
    Chief Scientific Officer & VP-Advanced Technology
  • Linda J. Park
    Secretary, Senior VP & Associate General Counsel













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2023?

18 brokers have issued 12 month price targets for Edwards Lifesciences' stock. Their EW share price forecasts range from $66.00 to $134.00. On average, they predict the company's stock price to reach $88.95 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2023?

Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 8.2% and is now trading at $80.76.
View the best growth stocks for 2023 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 12,770,000 shares, an increase of 6.8% from the February 13th total of 11,960,000 shares. Based on an average daily volume of 3,940,000 shares, the short-interest ratio is presently 3.2 days. Currently, 2.1% of the company's stock are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Tuesday, January, 31st. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.03. The medical research company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 26.05% and a net margin of 28.27%. The business's quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.51 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.45-$2.60 for the period, compared to the consensus estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (3.60%), Moneta Group Investment Advisors LLC (2.49%), Brown Advisory Inc. (2.32%), Geode Capital Management LLC (1.96%), Norges Bank (1.43%) and Amundi (1.31%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $80.76.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $48.95 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.44 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 17,300 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 3/25/2023 by MarketBeat.com Staff